9
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T82801 |
C12 NBD Galactosylceramide
|
||
C12 NBD galactosylceramide,一种荧光染料,作为半乳糖神经酰胺的生物活性衍生物,具有标记的荧光C12硝基苯并恶二唑(C12 NBD)基团。该化合物主要用于成像研究。 | |||
T36858 |
C12 Galactosylceramide (d18:1/12:0)
|
||
C12 Galactosylceramide is a bioactive sphingolipid. It inhibits IL-4 production by 53.84% in EL4 T cells when used at a concentration of 10 μM. C12 Galactosylceramide reduces the growth of human papillomavirus type 16-associated tumors in mice and reduces tumor recurrence following surgical removal or chemotherapy. It also reduces natural killer T cell activity, delays the onset of proteinuria, and improves survival in a mouse model of systemic lupus. | |||
T36323 |
C8 Galactosylceramide (d18:1/8:0)
C8 Galactosylceramide (d18:1/8:0) |
||
C8 Galactosylceramide is a synthetic C8 short-chain derivative of known membrane microdomain-forming sphingolipids. It increases the amount delivered and toxicity of doxorubicin in cancerous but not non-cancerous cells when incorporated into the nanoliposomal membrane of nanoliposomal-doxorubicin. C8 Galactosylceramide induces proliferation and cytokine production by splenocytes in vitro at concentrations ranging from 100-1,000 ng/ml but has no effect on natural killer T cell production in vivo.... | |||
T38281 |
C22 Galactosylceramide (d18:1/22:0)
|
||
C22 Galactosylceramide is a sphingolipid that has been found in the central nervous system.1,2C22 Galactosylceramide levels are increased in the spinal cord, but not the brain or liver, of mice fed a methionine-restricted diet.1C22 Galactosylceramide has been found in postmortem hippocampus from patients with Alzheimer's disease.2[Matreya, LLC.] | |||
T37872 |
C16 Galactosylceramide (d18:1/16:0)
C16 Galactosylceramide (d18:1/16:0) |
||
C16 Galactosylceramide is a glycosphingolipid that contains a galactose moiety attached to a ceramide acylated with palmitic acid . | |||
T38183 |
C18 3'-sulfo Galactosylceramide (d18:1/18:0)
C18 3'-sulfo Galactosylceramide (d18:1/18:0) |
||
C18 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. Levels of short-chain sulfatides, including C18 3'-sulfo galactosylceramide, decrease with age in mice and humans. It is increased in brain from mice with an arylsulfatase A deficiency (ASA-KO), particularly in lipid raft fractions. Plasma levels of C18 3'-sulfo galactosylceramide positively correlate with disability progression in patients with relapsing-remitting multiple sclerosis using the Expanded Disability ... | |||
T38185 |
C2 3'-sulfo Galactosylceramide (d18:1/2:0)
C2 3'-sulfo Galactosylceramide (d18:1/2:0) |
||
C2 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It has been used as an internal standard in the quantification of lysosulfatides in mouse brain tissue and plasma. | |||
T37440 |
C2 Adamantanyl Galactosylceramide (d18:1/2:0)
|
||
C2 Adamantanyl Galactosylceramide (d18:1/2:0) (AdaGalCer) is a bioactive sphingolipid. It reduces globotriaosylceramide 3 synthesis from exogenous lactosylceramide in microsomes. AdaGalCer stimulates recombinant glucocerebrosidase activity in a pH-dependent manner. It activates glucocerebrosidase to decrease glucosylceramide accumulation in fibroblasts and lymphoblasts isolated from patients with Gaucher and Fabry disease, respectively. | |||
T38184 |
C18:1 3'-sulfo Galactosylceramide (d18:1/18:1(9Z))
C18:1 3'-sulfo Galactosylceramide (d18:1/18:1(9Z)) |
||
C18:1 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It has been found in mouse brain. It has been used as a standard for the quantification of C18:1 3'-sulfo galactosylceramide in dried blood spots from patients with metachromatic leukodystrophy (MLD) by UPLC-MS. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T14193 |
α-Galactosylceramide
KRN7000,α-GalCer |
Others | Others |
α-Galactosylceramide (KRN7000) 是一种具有抗肿瘤和免疫刺激作用的合成糖脂。它是一种高效的 NKT 细胞激动剂,可与 CD1d 有效结合。它与 CD1d 的复合物可与 NKT 细胞的 T 细胞抗原受体结合。 |